7 reasons why I choose apixaban in everyday clinical practice Review article
Article Sidebar
Published:
Jun 30, 2019
Keywords:
apixaban, atrial fibrillation, stroke, major bleeding
Main Article Content
Abstract
Choosing a particular direct acting oral anticoagulant (DOAC) for a patient can be difficult as not all DOACs are the same. There is no evidence to recommend one agent over another because the DOACs have never been compared in randomized head-to-head trials. Hence the guiding principle has been to match the right drug to the right patient based on the dosing properties of each drug, the efficacy and safety and side effect profile as demonstrated in phase III trials and real world studies (RWS).
Article Details
How to Cite
Kręcki, R. (2019). 7 reasons why I choose apixaban in everyday clinical practice. Medycyna Faktow (J EBM), 12(2(43), 127-131. https://doi.org/10.24292/01.MF.0219.X
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Granger C.B., Alexander J.H., McMurray J.J. et al.: Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 2011; 365: 981-992.
2. Connolly S.J., Ezekowitz M.D., Yusuf S. et al.: Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 2009; 361: 1139-1151.
3. Patel M.R., Mahaffey K.W., Garg J. et al.: Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 2011; 365: 883-891.
4. Lip G.Y.H., Keshishian A., Li X. et al.: Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients. Stroke 2018; 49: 2933-2944.
5. Proietti M., Romanazzi I., Romiti G.F. et al.: Real-World Use of Apixaban for Stroke Prevention in Atrial Fibrillation. A Systematic Review and Meta-Analysis. Stroke 2018; 49: 98-106.
6. Abraham N.S., Noseworthy P., Yao X. et al.: Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study. Gastroenterology 2017; 152: 1014-1022.
7. Siontis K., Zhang X., Eckard A. et al.: Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States. Circulation 2018; 138: 1519-1529.
8. January C.T., Wann L.S., Calkins H. et al.: 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 2019; 139: e000-e000.
9. Ezekowitz M.D., Pollack C.V. Jr, Halperin J.L. et al.: Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial. Eur. Heart J. 2018; 39: 2959-2971.
10. Steffel J., Verhamme P., Potpara T.S. et al.: The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur. Heart J. 2018; 39: 1330-1393.
2. Connolly S.J., Ezekowitz M.D., Yusuf S. et al.: Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 2009; 361: 1139-1151.
3. Patel M.R., Mahaffey K.W., Garg J. et al.: Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 2011; 365: 883-891.
4. Lip G.Y.H., Keshishian A., Li X. et al.: Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients. Stroke 2018; 49: 2933-2944.
5. Proietti M., Romanazzi I., Romiti G.F. et al.: Real-World Use of Apixaban for Stroke Prevention in Atrial Fibrillation. A Systematic Review and Meta-Analysis. Stroke 2018; 49: 98-106.
6. Abraham N.S., Noseworthy P., Yao X. et al.: Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study. Gastroenterology 2017; 152: 1014-1022.
7. Siontis K., Zhang X., Eckard A. et al.: Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States. Circulation 2018; 138: 1519-1529.
8. January C.T., Wann L.S., Calkins H. et al.: 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 2019; 139: e000-e000.
9. Ezekowitz M.D., Pollack C.V. Jr, Halperin J.L. et al.: Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial. Eur. Heart J. 2018; 39: 2959-2971.
10. Steffel J., Verhamme P., Potpara T.S. et al.: The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur. Heart J. 2018; 39: 1330-1393.